On March 29, 2023 Genmab A/S (Nasdaq: GMAB) reported its Annual General Meeting, today at the Copenhagen Marriott Hotel, Copenhagen, Denmark (Press release, Genmab, MAR 29, 2023, View Source [SID1234629496]). At the meeting, Deirdre P. Connelly, Chair of the Board of Directors gave – on behalf of the Board of Directors – a report on the Company’s activities during the past year. Chief Executive Officer Dr. Jan van de Winkel presented the Company’s plans for 2023, and Chief Financial Officer Mr. Anthony Pagano presented the Annual Report for 2022 endorsed by the auditors. The report was approved, and discharge was given to the Board of Directors and the Executive Management.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
It was decided that the year’s profit of DKK 5,522 million be carried forward by transfer to retained earnings, as stated in the Annual Report.
The 2022 Compensation Report was approved.
Ms. Deirdre P. Connelly, Ms. Pernille Erenbjerg, Mr. Rolf Hoffmann, Dr. Paolo Paoletti, Dr. Anders Gersel Pedersen and Ms. Elizabeth O’Farrell were re-elected to the Board of Directors for a one-year period.
PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab was re-elected as the Company’s auditor.
The General Meeting adopted the proposals from the Board of Directors, as follows:
The proposal to adopt the Board of Directors’ remuneration for 2023.
The proposals to adopt an amended Remuneration Policy for the Board of Directors and the Executive Management.
The proposal to authorize the Board of Directors to mandate the Company to acquire treasury shares up to a nominal amount of DKK 500,000.